

# Scott E Snyder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2510949/publications.pdf>

Version: 2024-02-01

60  
papers

2,659  
citations

236612

25  
h-index

189595

50  
g-index

62  
all docs

62  
docs citations

62  
times ranked

3600  
citing authors

#	ARTICLE	IF	CITATIONS
1	[11C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence. Journal of Nuclear Medicine, 2021, , jnumed.120.261891.	2.8	4
2	Evaluation of <sup>11</sup> C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma. Journal of Nuclear Medicine, 2019, 60, 312-319.	2.8	18
3	Positron Emission Tomography Detects <i>In Vivo</i> Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma. Cancer Research, 2019, 79, 3112-3124.	0.4	28
4	<sup>18</sup> F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma. Journal of Nuclear Medicine, 2018, 59, 25-30.	2.8	39
5	Improved, one-pot synthesis of <sup>18</sup> F-fluorodopamine and quality control testing for use in patients with neuroblastoma. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 1069-1080.	0.5	13
6	A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence. International Urology and Nephrology, 2018, 50, 2153-2165.	0.6	37
7	Molecular Detection and Analysis of Exosomes Using Surface-Enhanced Raman Scattering Gold Nanorods and a Miniaturized Device. Theranostics, 2018, 8, 2722-2738.	4.6	173
8	<sup>11</sup> C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma. Journal of Neuro-Oncology, 2017, 132, 163-170.	1.4	19
9	Thermolysis and radiofluorination of diaryliodonium salts derived from anilines. Organic and Biomolecular Chemistry, 2017, 15, 2246-2252.	1.5	17
10	Comparison of <sup>11</sup> C-Methionine and <sup>18</sup> F-FDG PET/CT for Staging and Follow-up of Pediatric Lymphoma. Journal of Nuclear Medicine, 2017, 58, 419-424.	2.8	19
11	Both Financial and Cognitive Decline Predict Clinical Progression in MCI. Alzheimer Disease and Associated Disorders, 2016, 30, 27-34.	0.6	17
12	Efficient automated syntheses of high specific activity 6- <sup>18</sup> F-fluorodopamine using a diaryliodonium salt precursor. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 30-34.	0.5	21
13	A Collaborative Assessment Among 11 Pharmaceutical Companies of Misinformation in Commonly Used Online Drug Information Compendia. Annals of Pharmacotherapy, 2016, 50, 352-359.	0.9	14
14	Enhancing both CT imaging and natural killer cell-mediated cancer cell killing by a GD2-targeting nanoconstruct. Journal of Materials Chemistry B, 2016, 4, 513-520.	2.9	26
15	FDG PET/CT imaging of desmoplastic small round cell tumor: findings at staging, during treatment and at follow-up. Pediatric Radiology, 2015, 45, 1308-1315.	1.1	25
16	A Practical, Automated Synthesis of <i>meta</i> - <sup>18</sup> F-Fluorobenzylguanidine for Clinical Use. ACS Chemical Neuroscience, 2015, 6, 1870-1879.	1.7	29
17	Targeting the DNA Repair Pathway in Ewing Sarcoma. Cell Reports, 2014, 9, 829-840.	2.9	141
18	Evaluation of children with craniopharyngioma using carbon-11 methionine PET prior to proton therapy. Neuro-Oncology, 2013, 15, 506-510.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Evaluation of the Biodistribution of <sup>11</sup> C-Methionine in Children and Young Adults. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1902-1908.	2.8	32
20	<sup>64</sup> Cu- <sup>67</sup> Zn-NH <sub>2</sub> -Bn-DOTA-hu14.18K322A, a PET Radiotracer Targeting Neuroblastoma and Melanoma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1772-1778.	2.8	26
21	Histiocyte-rich Xanthomatous Pseudotumor Mimicking Relapse on Positron Emission Tomography Imaging in an Adolescent With Primary Mediastinal Diffuse Large B-cell Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 232-235.	0.3	11
22	Bioidentical thyroid replacement therapy in practice: Delivering a physiologic T4:T3 ratio for improved patient outcomes with the Listek-Snyder protocol. <i>International Journal of Pharmaceutical Compounding</i> , 2012, 16, 376-80.	0.0	6
23	Steering Carbon Nanotubes to Scavenger Receptor Recognition by Nanotube Surface Chemistry Modification Partially Alleviates NF $\kappa$ B Activation and Reduces Its Immunotoxicity. <i>ACS Nano</i> , 2011, 5, 4581-4591.	7.3	84
24	Leading Neuroblastoma Cells To Die by Multiple Premeditated Attacks from a Multifunctionalized Nanoconstruct. <i>Journal of the American Chemical Society</i> , 2011, 133, 13918-13921.	6.6	30
25	Repeated administrations of carbon nanotubes in male mice cause reversible testis damage without affecting fertility. <i>Nature Nanotechnology</i> , 2010, 5, 683-689.	15.6	258
26	Clinical Interview Assessment of Financial Capacity in Older Adults with Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 806-814.	1.3	97
27	International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1-year results. <i>Journal of Vascular Surgery</i> , 2008, 47, 247-257.e3.	0.6	335
28	5-tert-Butyl-2-(4- <sup>18</sup> F-fluoropropynylphenyl)-1,3-dithiane oxides: potential new GABAA receptor radioligands. <i>Nuclear Medicine and Biology</i> , 2008, 35, 549-559.	0.3	4
29	Tensile Strength Comparison of Small Intestinal Submucosa Body Wall Repair. <i>Journal of Surgical Research</i> , 2006, 135, 9-17.	0.8	33
30	In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. <i>Annals of Neurology</i> , 2006, 59, 13-20.	2.8	61
31	Imaging butyrylcholinesterase activity in Alzheimer's disease. <i>Annals of Neurology</i> , 2006, 60, 746-746.	2.8	1
32	Evaluation of <sup>18</sup> F-labeled acetylcholinesterase substrates as PET radiotracers. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 869-875.	1.4	12
33	Chemistry of Fluorine-18 Radiopharmaceuticals. , 2005, , 195-227.		5
34	N-methylpiperidinemethyl, N-methylpyrrolidyl and N-methylpyrrolidinemethyl esters as PET radiotracers for acetylcholinesterase activity. <i>Nuclear Medicine and Biology</i> , 2003, 30, 293-302.	0.3	15
35	N-[ <sup>18</sup> F]fluoroethylpiperidinyl, n-[ <sup>18</sup> F]fluoroethylpiperidinemethyl and n-[ <sup>18</sup> F]fluoroethylpyrrolidinyl esters as radiotracers for acetylcholinesterase. <i>Nuclear Medicine and Biology</i> , 2003, 30, 491-500.	0.3	13
36	Cloning, expression, purification, and biological activity of five feline type I interferons. <i>Veterinary Immunology and Immunopathology</i> , 2002, 89, 13-27.	0.5	22

#	ARTICLE	IF	CITATIONS
37	Effect of stereochemistry on ester hydrolysis by cholinesterases: Implications for radiotracer design. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, S110.	0.5	0
38	Radiolabeled Cholinesterase Substrates: In Vitro Methods for Determining Structure-Activity Relationships and Identification of a Positron Emission Tomography Radiopharmaceutical for In Vivo Measurement of Butyrylcholinesterase Activity. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 132-143.	2.4	43
39	Acetylcholinesterase Inhibition Increases in Vivo N-(2-[18F]Fluoroethyl)-4-piperidyl Benzilate Binding to Muscarinic Acetylcholine Receptors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 144-148.	2.4	12
40	Dual-[11C]Tracer Single-Acquisition Positron Emission Tomography Studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 1480-1492.	2.4	62
41	Do In Vitro Enzyme Kinetics Predict In Vivo Radiotracer Kinetics?. , 2001, , 105-108.		2
42	Assessing Financial Capacity in Patients With Alzheimer Disease. <i>Archives of Neurology</i> , 2000, 57, 877.	4.9	279
43	Synthesis and in vivo evaluation of (E)-N-[11C]Methyl-4-(3-pyridinyl)-3-butene-1-amine ([11C]metanicotine) as a nicotinic receptor radioligand. <i>Nuclear Medicine and Biology</i> , 2000, 27, 415-418.	0.3	7
44	Synthesis, 18F-Labeling, and Biological Evaluation of Piperidyl and Pyrrolidyl Benzilates as in Vivo Ligands for Muscarinic Acetylcholine Receptors. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4552-4562.	2.9	27
45	Kinetic Modeling of N-[11C]Methylpiperidin-4-yl Propionate: Alternatives for Analysis of an Irreversible Positron Emission Tomography Tracer for Measurement of Acetylcholinesterase Activity in Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 1150-1163.	2.4	102
46	( $\alpha$ )-6 $\alpha$ -[11C]Dihydroroten-12 $\beta$ -ol (( $\alpha$ )-[11C]DHROL) for in vivo measurement of mitochondrial Complex I. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1999, 42, 641-652.	0.5	5
47	Synthesis and evaluation of 6-[11C]Methoxy-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-1,2-benzisoxazole as an in vivo radioligand for acetylcholinesterase. <i>Nuclear Medicine and Biology</i> , 1999, 26, 99-103.	0.3	19
48	Simplified methods for in vivo measurement of acetylcholinesterase activity in rodent brain. <i>Nuclear Medicine and Biology</i> , 1999, 26, 543-550.	0.3	15
49	Synthesis of 1-[11c]methylpiperidin-4-yl propionate ([11c]pmp) for in vivo measurements of acetylcholinesterase activity. <i>Nuclear Medicine and Biology</i> , 1998, 25, 751-754.	0.3	62
50	N-[11C]methylpiperidine esters as acetylcholinesterase substrates: an in vivo structure-reactivity study. <i>Nuclear Medicine and Biology</i> , 1998, 25, 755-760.	0.3	11
51	Syntheses of carbon-11 labeled piperidine esters as potential in vivo substrates for acetylcholinesterase. <i>Nuclear Medicine and Biology</i> , 1998, 25, 761-768.	0.3	8
52	One for All or One for Each? Matching Radiotracers and Regional Brain Pharmacokinetics 1 1Transcripts of the BRAINPET97 discussion of this chapter can be found in Section VIII., 1998, , 261-265.		2
53	Reply to HS Kahn. <i>American Journal of Clinical Nutrition</i> , 1997, 66, 712-713.	2.2	15
54	Synthesis of carbon-11- and fluorine-18-labeled 1-methyl-4-piperidyl- $\alpha$ -fluorobenzoate and their biodistribution in mice. <i>Nuclear Medicine and Biology</i> , 1996, 23, 513-517.	0.3	14

#	ARTICLE	IF	CITATIONS
55	8,9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: A Potent Full Dopamine D1 Agonist Containing a Rigid $\beta$ -Phenyldopamine Pharmacophore. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 549-555.	2.9	57
56	In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[11C]methylpiperidin-4-yl propionate ([11C]PMP)., 1996, 22, 123-131.		98
57	Synthesis of Carbon-11-, Fluorine-18-, and Iodine-125-Labeled GABAA-Gated Chloride Ion Channel Blockers: Substituted 5-tert-Butyl-2-phenyl-1,3-dithianes and -dithiane Oxides. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 2663-2671.	2.9	10
58	Synthesis and Evaluation of 6,7-Dihydroxy-2,3,4,8,9,13b-hexahydro-1H-benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-Dihydroxy-1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(Aminomethyl)-9,10-dihydro-1,2-dihydroxyanthracene as Conformationally Restricted Analogs of $\beta$ -Phenyldopamine. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 2395-2409.	2.9	69
59	2,3-Dihydrobenzofuran analogs of hallucinogenic phenethylamines. <i>Journal of Medicinal Chemistry</i> , 1991, 34, 276-281.	2.9	39
60	Synthesis of L-[methyl-11C]Methionine ([11C]MET)., 0, , 199-212.		5